Yunnan Baiyao Group stock (CNE100000G78): traditional Chinese medicine player on investors’ radar

Yunnan Baiyao Group, a well?known Chinese producer of traditional Chinese medicine and modern healthcare products, remains part of major mainland indices and in focus for investors watching China’s healthcare and consumer health trends.

Yunnan Baiyao Group is one of China’s best-known manufacturers of traditional Chinese medicine and modern health products and its shares trade on the Shenzhen Stock Exchange under the ticker 000538, according to index data such as the CSI 300 components list from Investing.com as of 05/20/2026. The company’s products range from hemostatic powders and capsules to toothpaste and other over-the-counter health items, giving it a broad footprint in the domestic healthcare and consumer sectors.

As of: 05/21/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Yunnan Baiyao Group
• Sector/industry: Healthcare, traditional Chinese medicine, consumer health
• Headquarters/country: Kunming, China
• Core markets: Mainland China; selected overseas markets via exports and partnerships
• Key revenue drivers: Traditional Chinese medicine products, oral care, OTC healthcare items
• Home exchange/listing venue: Shenzhen Stock Exchange (ticker 000538)
• Trading currency: Chinese yuan (CNY)

Yunnan Baiyao Group: core business model

Yunnan Baiyao Group focuses on traditional Chinese medicine and modern healthcare products, combining legacy formulations with contemporary manufacturing and distribution platforms. The brand’s signature hemostatic powder and related products have been widely recognized in China for decades and form a key part of its identity, according to background descriptions from financial press coverage such as Ad-hoc-news as of 03/2024. Over time, the group has expanded into broader consumer health categories, including oral care and wellness.

The company’s model relies on leveraging brand recognition in traditional Chinese medicine while diversifying into modern formulations and formats that fit evolving consumer preferences. Yunnan Baiyao Group distributes its products through pharmacies, hospitals, and retail channels in China and increasingly through e-commerce platforms, which have become an important route to reach younger and more urban consumers. This multi-channel approach allows the company to tap into both medical use cases and everyday health and wellness needs, while navigating regulatory frameworks applicable to pharmaceutical and OTC products.

In addition to its domestic focus, Yunnan Baiyao Group has gradually increased its presence in overseas markets through exports and partnerships, though international sales remain smaller compared with domestic revenue. For US-based investors, the company is relevant as part of China’s healthcare and consumer health ecosystem, an area targeted by policymakers for development and innovation. Exposure to this segment can be obtained indirectly through Chinese equity indices or funds that include Yunnan Baiyao Group among their holdings, reflecting its role as a notable player in the traditional Chinese medicine segment.

Main revenue and product drivers for Yunnan Baiyao Group

Yunnan Baiyao Group’s revenue is anchored in its portfolio of hemostatic and pain-relief products derived from traditional formulations, which are used in clinical settings and by individual consumers. These offerings include powders, capsules, and other dosage forms that address bleeding and trauma-related scenarios, where the brand has historical recognition. At the same time, the company has developed a wide range of oral care products, such as toothpaste and mouthwash, which have become major contributors to sales as Chinese consumers increase spending on personal care and hygiene.

The company also participates in broader OTC healthcare categories, offering products designed for wound care, pain management, and general wellness. This mix helps balance demand from hospital channels with retail and e-commerce sales, potentially smoothing fluctuations tied to healthcare policy changes or hospital procurement cycles. Investor materials and market commentary suggest that Yunnan Baiyao Group’s strategy has emphasized brand-driven growth and product upgrades, for example by introducing new variants of toothpaste or enhanced formulations of existing products, according to summaries from Chinese financial media referenced by Investing.com as of 05/20/2026.

Another key driver is the company’s ability to manage its supply chain and raw material sourcing for herbal ingredients, which is essential to maintaining product consistency and meeting regulatory standards. Investments in manufacturing technology and quality control can support exports and the registration of products in additional markets, although regulatory pathways can vary significantly by country. For international investors, understanding how much of Yunnan Baiyao Group’s revenue is generated from mature core products versus new categories or channels is important for assessing the company’s growth profile, even though detailed segment data may only be available through periodic reports in Chinese language.

Industry trends and competitive position

The broader Chinese healthcare and consumer health market is influenced by demographic changes, rising incomes, and policy initiatives aimed at improving access to care and supporting domestic innovation. Traditional Chinese medicine retains a strong role in China’s healthcare system and consumer culture, creating a sizable addressable market for companies like Yunnan Baiyao Group. At the same time, competition has intensified as other established brands and newer entrants expand their portfolios and marketing efforts, particularly in high-growth categories such as oral care and wellness supplements, according to sector analyses from business media summaries based on China healthcare data published in recent years.

Yunnan Baiyao Group’s competitive position is supported by strong brand recognition within its core hemostatic and trauma-related product categories, where its flagship formulations are widely known. In oral care and consumer products, the company competes with both domestic rivals and international multinationals that market toothpaste and related items to Chinese consumers. Brand loyalty, perceived efficacy, and pricing all play roles in shaping market share dynamics. Additionally, digital channels and social commerce are increasingly important, as consumers discover and evaluate products through online platforms and influencers.

From a regulatory and policy standpoint, traditional Chinese medicine manufacturers must comply with standards governing quality, labeling, and claims, and the government periodically updates its policies on reimbursement and hospital procurement. For companies like Yunnan Baiyao Group, changes in these frameworks can influence the mix of sales between hospital, pharmacy, and retail channels. Investors tracking the sector often monitor announcements from Chinese health regulators and industry associations, as well as company-specific disclosures, to understand how policy changes may impact margins and growth trajectories.

Why Yunnan Baiyao Group matters for US investors

For US investors, Yunnan Baiyao Group offers insight into China’s traditional Chinese medicine industry and the integration of heritage brands into modern consumer health markets. While the stock primarily trades on the Shenzhen exchange in CNY, it can be included in indices that are tracked by global funds, giving overseas investors indirect exposure. As China continues to promote domestic healthcare and wellness consumption, companies with established brands and diversified product ranges, such as Yunnan Baiyao Group, may play an important role in sector-level trends watched by international investors, according to index inclusion lists and fund disclosures that reference its presence in major benchmarks, including those listed on Investing.com as of 05/20/2026.

US-based readers also often encounter Yunnan Baiyao-branded products through specialty retailers or e-commerce platforms that sell traditional Chinese medicine items to consumers and pet owners. Some sites describe the capsules and powders as being used for bleeding control and wound care in both humans and animals, highlighting the brand’s recognition outside mainland China, according to product descriptions on international retailers such as BestChineseMedicines as of 05/2026. These retail channels operate under local regulations and should not be confused with the company’s own investor communications, but they illustrate how the Yunnan Baiyao name circulates in global consumer markets.

It is also relevant for US investors that Chinese equity exposure, including healthcare names, can be subject to currency movements, regulatory developments, and geopolitical headlines affecting capital flows. Yunnan Baiyao Group’s business is predominantly domestic, so trends in Chinese consumption, healthcare policy, and digital retail infrastructure have a direct influence on its operating environment. When considering such stocks via funds or other instruments, investors often assess how portfolio holdings align with their risk tolerance for emerging markets, regulatory complexity, and foreign exchange volatility.

Conclusion

Yunnan Baiyao Group is a prominent player in China’s traditional Chinese medicine and consumer health space, anchored by its well-known hemostatic products and an expanding portfolio of oral care and OTC offerings. Its listing on the Shenzhen Stock Exchange and presence in major mainland indices helps keep the stock visible to both domestic and international investors who gain exposure through China-focused funds and benchmarks. For US investors, the company provides a window into the evolution of traditional medicine brands amid broader shifts in Chinese healthcare policy, consumer behavior, and digital distribution. At the same time, the investment case involves typical emerging market considerations such as currency risk, regulatory complexity, and the need to interpret company disclosures that may be primarily available in Chinese. As with any equity exposure, a balanced view of opportunities and risks, including sector and country-specific factors, remains important when assessing the role of Yunnan Baiyao Group within a diversified portfolio.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.